EichorEICHOR
Condition: Hereditary Transthyretin Mediated Amyloid Polyneuropathy Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Hereditary Transthyretin Mediated Amyloid Polyneuropathy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Phase N/A · 82 location(s) · AstraZeneca · NCT06465810A Phase 3 Study of NTLA-2001 in ATTRv-PN
Phase 3 · 14 location(s) · Intellia Therapeutics · NCT06672237ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Phase N/A · 40 location(s) · Alnylam Pharmaceuticals · NCT04561518TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos
Phase 3 · 41 location(s) · Alnylam Pharmaceuticals · NCT07223203Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Phase N/A · 7 location(s) · Alnylam Pharmaceuticals · NCT05040373
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.